AI assistant
KALA BIO, Inc. — Director's Dealing 2020
Jun 30, 2020
35091_dirs_2020-06-29_a4b9d839-ed85-4e6e-80b1-c1edab9b0d5a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2020-06-25
Reporting Person: Paull Robert Bradley (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-06-25 | Common Stock | A | 20000 | — | Acquired | 20000 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2361 | Indirect |
Footnotes
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the earlier of (i) June 25, 2021 or (ii) the date of the first annual meeting following June 25, 2020.
F2: Includes 20,000 unvested RSUs
F3: These shares are owned directly by the Paull Revocable Trust U/A/D 04/06/2012 (the "Trust"), and indirectly by Mr. Paull as co-trustee of the Trust.